A total of 120 people with type 2 diabetes (HbA 1c 48 mmol/mol [6.5%]) and at high risk of CVD (age 50 years) were randomised into four parallel groups ( n =30 in each group) for 32 weeks: 1.0 mg semaglutide (open label)
Wegovy Side Effects : Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis
Mounjaro and Zepbound contain tirzepatide, which targets two hormones instead of one, potentially producing stronger appetite suppression and greater weight loss for people who have plateaued on semaglutide alone
We urge our patients to discuss with us or a pharmacist to gain a full understanding of the potential costs and savings associated with each medication
GLP-1 medications reduce overall food intake, and many patients naturally reduce refined carbohydrate consumption as appetite suppression shifts food preferences toward higher-protein, lower-sugar options
